-
| Industry | Medical Devices |
|---|---|
| Sector | Healthcare |
| ISIN | US29415J1060 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Beta | 1.28 |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 23 |
| PE Ratio | None |
| Market Cap | 46M |
enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NVNO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024